AbCellera Biologics (ABCL) Set to Post Quarterly Earnings on Monday

AbCellera Biologics (NASDAQ:ABCL – Get Free Report) is expected to be releasing its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect the company to announce earnings of ($0.1706) per share and revenue of $8.41 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Monday, November 9, 2026 at 5:00 PM ET.

AbCellera Biologics (NASDAQ:ABCL – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). The company had revenue of $4.05 million for the quarter, compared to analyst estimates of $7.85 million. AbCellera Biologics had a negative return on equity of 17.49% and a negative net margin of 248.83%. On average, analysts expect AbCellera Biologics to post ($0.69) EPS for the current fiscal year and ($0.82) EPS for the next fiscal year.

AbCellera Biologics Stock Performance

Shares of ABCL stock opened at $11.88 on Friday. The company has a market capitalization of $3.64 billion, a price-to-earnings ratio of -22.00 and a beta of 1.59. The company has a 50-day simple moving average of $12.28 and a 200 day simple moving average of $7.04. AbCellera Biologics has a 52 week low of $2.74 and a 52 week high of $15.02.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. JPMorgan Chase & Co. started coverage on shares of AbCellera Biologics in a report on Tuesday, September 29th. They issued an “overweight” rating and a $17.00 price target on the stock. Cantor Fitzgerald boosted their price objective on AbCellera Biologics from $11.00 to $12.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Stifel Nicolaus upped their target price on AbCellera Biologics from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Truist Financial upped their target price on AbCellera Biologics from $12.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AbCellera Biologics in a research note on Thursday, October 15th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.78.

View Our Latest Research Report on ABCL

AbCellera Biologics Company Profile

(Get Free Report)

AbCellera Biologics Inc is a biotechnology company headquartered in Vancouver, British Columbia, that develops antibody-based medicines and provides antibody discovery services to pharmaceutical and biotechnology companies. Its platform is designed to identify therapeutic antibodies from immune cells and accelerate their progression from discovery through development.

The company combines high-throughput screening, microfluidics, single-cell analysis, automation, and artificial intelligence to evaluate large numbers of antibody candidates.

Read More

Earnings History for AbCellera Biologics (NASDAQ:ABCL)

Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.